New heart drug atorvo+™ passes first safety check in healthy volunteers
NCT ID NCT06615284
First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This early-stage study tested the safety and how the body processes a new drug called Atorvo+™ in 24 healthy adults aged 40 to 75. The main goal was to check for side effects and measure drug levels in the blood. Since it was a Phase 1 trial in healthy people, it did not aim to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nucleus Network
Melbourne, Australia
Conditions
Explore the condition pages connected to this study.